COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			1 Months Ended		12 Months Ended
	Feb. 06, 2021	Jul. 09, 2019	Jan. 31, 2021	Jan. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Nov. 15, 2019
Net Investment Income [Line Items]
Research and development expenses					$ 15,538,122	$ 4,694,349
Up-front payment					10,000,000		$ 10,000,000
Payment for expenditures					$ 760,000		$ 760,000
Common stock received					185,053
Common stock issued					59,835
Common stock reserved for issuance					17,414	82,237
Compensation description					The Company had an agreement with Dr. Dybul, the Company’s Executive Vice-Chair, whereby he fulfilled the duties as prescribed by the Company’s bylaws and received annual compensation in the amount of $430,000, plus options to purchase 300,000 shares of Common Stock that vested immediately. Dr. Dybul was given a one-time grant of options to purchase 450,000 shares of Common Stock at a strike price of $8.00 per share on June 11, 2020. As of July 1, 2021, this agreement was terminated upon Dr. Dybul becoming the Company’s full-time CEO (see Note 10.) The Company has a consulting agreement for services of a Senior Medical Advisor for $210,000 per year on a part-time basis.
G-Tech [Member] | License Agreement [Member]
Net Investment Income [Line Items]
Payment for license	$ 1,200,000			$ 1,200,000
Royalty Percentage			$ 0.02
Consulting Agreement [Member] | G-Tech [Member]
Net Investment Income [Line Items]
Consulting expenses		$ 130,000
Monthly consulting fee					$ 25,000
Research and development expenses					275,000	$ 1,125,000
Monthly research costs					144,500
Payment for scientific staffing resources					$ 2,409,000	$ 1,022,000